suramin has been researched along with Lassitude in 4 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity." | 6.77 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| " We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity." | 2.77 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| " Regular pharmacokinetic sampling of plasma and ascites fluid was carried out." | 2.69 | Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. ( Baars, JP; Beijnen, JH; Dubbelman, R; Moolenaar, WH; Rodenhuis, S; Westermann, AM, 2000) |
| "This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine the ability of an adaptive control with feedback (ACF) dosing strategy to maintain suramin plasma concentrations within a preselected range; (3) to develop a population model of suramin pharmacokinetics; and (4) to identify preliminary evidence of antitumor activity." | 2.68 | Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ( Eisenberger, MA; Hemady, RK; Jacobs, SC; Jodrell, DI; Lowitt, MH; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1995) |
| "We used population pharmacokinetic-parameter estimates and designed a fixed dosing schedule to maintain plasma suramin concentrations between 100 and 300 micrograms/mL and then evaluated its performance." | 2.68 | Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. ( Egorin, MJ; Eisenberger, MA; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Zuhowski, EG, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lustberg, MB | 1 |
| Pant, S | 1 |
| Ruppert, AS | 1 |
| Shen, T | 1 |
| Wei, Y | 1 |
| Chen, L | 1 |
| Brenner, L | 1 |
| Shiels, D | 1 |
| Jensen, RR | 1 |
| Berger, M | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Grever, M | 1 |
| Au, JL | 1 |
| Wientjes, MG | 1 |
| Shapiro, CL | 1 |
| Eisenberger, MA | 2 |
| Sinibaldi, VJ | 2 |
| Reyno, LM | 2 |
| Sridhara, R | 2 |
| Jodrell, DI | 1 |
| Zuhowski, EG | 2 |
| Tkaczuk, KH | 1 |
| Lowitt, MH | 1 |
| Hemady, RK | 1 |
| Jacobs, SC | 1 |
| Egorin, MJ | 1 |
| Westermann, AM | 1 |
| Dubbelman, R | 1 |
| Baars, JP | 1 |
| Moolenaar, WH | 1 |
| Beijnen, JH | 1 |
| Rodenhuis, S | 1 |
4 trials available for suramin and Lassitude
| Article | Year |
|---|---|
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2012 |
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Topics: Adaptation, Physiological; Aged; Anorexia; Bayes Theorem; Cohort Studies; Drug Monitoring; Drug Resi | 1995 |
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring | 1995 |
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Topics: Adult; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Dru | 2000 |